We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Epigenetic Test Could Determine Efficacy of New Immunotherapy Treatments Against Multiple Myeloma

By LabMedica International staff writers
Posted on 11 Oct 2024
Print article
Image: Bone marrow affected by multiple myeloma, a disease against which PVR inhibition can increase the efficacy of immunotherapy (Photo courtesy of Cancer Epigenetics Group, IJC)
Image: Bone marrow affected by multiple myeloma, a disease against which PVR inhibition can increase the efficacy of immunotherapy (Photo courtesy of Cancer Epigenetics Group, IJC)

Multiple myeloma is a blood cancer that primarily affects individuals over the age of sixty, and its occurrence rises as the population ages. In this disease, the bone marrow—the spongy tissue inside bones that produces normal blood cells—becomes overrun by abnormal plasma cells. Under normal conditions, plasma cells are part of the immune system, helping to fight infections, but in multiple myeloma, they become malignant, damaging the bone marrow and spreading to other areas such as the spine, skull, pelvis, and ribs. While current treatments can manage the disease for extended periods, a definitive cure remains elusive. However, advancements in immunotherapy, including the use of antibodies and engineered immune cells, have opened new possibilities for treating patients who relapse or are resistant to standard therapies.

Now, researchers at Josep Carreras Leukemia Research Institute (IJC, Barcelona, Spain) have demonstrated an epigenetic test that predicts the effectiveness of new immunotherapy treatments for multiple myeloma. In a study published in Leukemia, a journal from the Nature group, the team focused on identifying genes altered in cancer that are involved in immune system function and antigen recognition. This led them to discover a subgroup of multiple myeloma patients with an epigenetic modification in the PVR gene, a key immune system regulator, which resulted in the gene losing its activity.

The researchers observed that patients with this PVR gene defect experienced a better disease progression, leading them to hypothesize that cancer cells in these individuals might be more susceptible to immune system attacks. To test this idea, they used a cellular model of multiple myeloma, eliminating the PVR gene to observe how the cells responded to various immunotherapy approaches, including antibodies, T-lymphocytes, and genetically engineered natural killer cells (CAR-T cells). In all instances, the immune response effectively targeted and attacked the tumor cells in vitro. This discovery could help clinicians identify which patients are likely to benefit most from immunotherapy, improving personalized treatment strategies and clinical management.

“Our results demonstrate that in this malignant blood disease, inhibiting the PVR gene decisively increases the probability of success of immunotherapy,” said Dr. Manel Esteller, ICREA Research Professor at IJC, who directed the research “Now, then, it would be the turn of the pharmaceutical industry and clinical research to bring these results to the bedside of the patient."

Related Links:
IJC

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Automated Blood Typing System
IH-500 NEXT
New
Urine Collection Container
Urine Monovette
New
Silver Member
Rubella Infection ELISA
ReQuest RUBELLA IgM ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: LMU’s Professor Frederick Klauschen developed the novel approach that can improve diagnostic accuracy (Photo courtesy of LMU Munich)

AI Tool Uses Imaging Data to Detect Less Frequent GI Diseases

Artificial intelligence (AI) is already being utilized in various medical fields, demonstrating significant potential in aiding doctors in diagnosing diseases through imaging data. However, training AI... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.